The tramadol option

被引:52
作者
Desmeules, JA
机构
[1] Univ Hosp, Div Clin Pharmacol, Dept Anaesthesiol, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp, Multidisciplinary Pain Ctr, CH-1211 Geneva 14, Switzerland
关键词
D O I
10.1053/eujp.2000.0206
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
Tramadol is an option for the treatment of rheumatological pain. Its mode of action and safety profile distinguishes it from other opioids. Tramadol differs from other opioids by combining a weak opioid and a monoaminergic mode of action. It is effective in different types of moderate-to-severe pain, including neuropathic pain. Moreover, as the mode of action of tramadol does not overlap with that of NSAIDs, it is a useful agent to be combined with these drugs. Tramadol induces fewer opioid adverse reactions for a given level of analgesia compared with traditional opioids. Common adverse reactions of tramadol such as nausea and dizziness, which usually occur only at the beginning of therapy and attenuate over time, can be further minimized by up-titrating the drug over several days. Dose adjustment is only necessary in patients over 75 years of age, or in those with either hepatic or renal insufficiency. Tramadol should be avoided or used with caution in epileptics, or in individuals who are receiving seizure-threshold lowering drugs. Finally, tramadol has a low risk of abuse because it has only a weak opioid effect and its monoaminergic action could inhibit the development of dependence. The low abuse potential of tramadol has been demonstrated by postmarketing surveillance data. (C) 2000 European Federation of Chapters of the International Association for the Study of Pain.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 22 条
[1]
AHTEE L, 1989, J PHARMACOL EXP THER, V249, P303
[2]
[Anonymous], 1995, REV CONTEMP PHARMACO
[3]
The clinical use of tramadol hydrochloride [J].
Bamigbade, TA ;
Langford, RM .
PAIN REVIEWS, 1998, 5 (03) :155-182
[4]
A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States [J].
Cicero, TJ ;
Adams, EH ;
Geller, A ;
Inciardi, JA ;
Muñoz, A ;
Schnoll, SH ;
Senay, EC ;
Woody, GE .
DRUG AND ALCOHOL DEPENDENCE, 1999, 57 (01) :7-22
[5]
BIOACTIVATION OF THE NARCOTIC DRUG CODEINE IN HUMAN-LIVER IS MEDIATED BY THE POLYMORPHIC MONOOXYGENASE CATALYZING DEBRISOQUINE 4-HYDROXYLATION (CYTOCHROME-P-450 DBL/BUFI) [J].
DAYER, P ;
DESMEULES, J ;
LEEMANN, T ;
STRIBERNI, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 152 (01) :411-416
[6]
IMPACT OF ENVIRONMENTAL AND GENETIC-FACTORS ON CODEINE ANALGESIA [J].
DESMEULES, J ;
GASCON, MP ;
DAYER, P ;
MAGISTRIS, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (01) :23-26
[7]
DESMEULES J, 2000, JOINT M 7 WORLD C CL, P187
[8]
Contribution of monoaminergic modulation to the analgesic effect of tramadol [J].
Desmeules, JA ;
Piguet, V ;
Collart, L ;
Dayer, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (01) :7-12
[9]
GOBEL H, 1995, CLIN DRUG INVEST, V10, P208
[10]
Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy [J].
Harati, Y ;
Gooch, C ;
Swenson, M ;
Edelman, S ;
Greene, D ;
Raskin, P ;
Donofrio, P ;
Cornblath, D ;
Sachdeo, R ;
Siu, CO ;
Kamin, M .
NEUROLOGY, 1998, 50 (06) :1842-1846